Individual risk evaluation for local recurrence and distant metastasis in Ewing sarcoma: A multistate model A multistate model for Ewing sarcoma

被引:19
|
作者
Bosma, S. E. [1 ]
Rueten-Budde, A. J. [2 ]
Lancia, C. [2 ]
Ranft, A. [3 ,4 ]
Dirksen, U. [3 ,4 ]
Krol, A. D. [5 ]
Gelderblom, H. [6 ]
van de Sande, M. A. J. [1 ]
Dijkstra, P. D. S. [1 ]
Fiocco, M. [2 ,7 ]
机构
[1] Leiden Univ, Med Ctr, Dept Orthoped, Albinusdreef 2, NL-2333 ZA Leiden, Netherlands
[2] Leiden Univ, Math Inst, Leiden, Netherlands
[3] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Sarcoma Ctr,German Canc Consortium,Pediat 3, Essen, Germany
[4] German Canc Consortium DKTK, Essen, Germany
[5] Leiden Univ, Med Ctr, Dept Radiotherapy, Leiden, Netherlands
[6] Leiden Univ, Med Ctr, Dept Med Oncol, Leiden, Netherlands
[7] Leiden Univ, Med Ctr, Med Stat Biomed Data Sci, Leiden, Netherlands
基金
欧盟第七框架计划;
关键词
Ewing sarcoma; multistate model; personalized medicine; prediction; survival; PROGNOSTIC-FACTORS; CHEMOTHERAPY; TUMORS; BONE; EXPERIENCE; SURVIVAL; ADJUVANT; SURGERY; THERAPY; PROGRAM;
D O I
10.1002/pbc.27943
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We investigated the effects of surgical margins, histological response, and radiotherapy on local recurrence (LR), distant metastasis (DM), and survival in Ewing sarcoma. Procedure Disease evolution was retrospectively studied in 982 patients with Ewing sarcoma undergoing surgery after chemotherapy using a multistate model with initial state surgery, intermediate states LR, pulmonary metastasis (DMpulm), other DM +/- LR (DMother), and final state death. Effect of risk factors was estimated using Cox proportional hazard models. Results The median follow-up was 7.6 years (95% CI, 7.2-8.0). Risk factors for LR are pelvic location, HR 2.04 (1.10-3.80), marginal/intralesional resection, HR 2.28 (1.25-4.16), and radiotherapy, HR 0.52 (0.28-0.95); for DMpulm the risk factors are <90% necrosis, HR 2.13 (1.13-4.00), and previous pulmonary metastasis, HR 4.90 (2.28-8.52); for DMother are 90% to 99% necrosis, HR 1.56 (1.09-2.23), <90% necrosis, HR 2.66 (1.87-3.79), previous bone/other metastasis, HR 3.08 (2.03-4.70); and risk factors for death without LR/DM are pulmonary metastasis, HR 8.08 (4.01-16.29), bone/other metastasis, HR 10.23 (4.90-21.36), and <90% necrosis, HR 6.35 (3.18-12.69). Early LR (0-24 months) negatively influences survival, HR 3.79 (1.34-10.76). Once DMpulm/DMother arise only previous bone/other metastasis remain prognostic for death, HR 1.74 (1.10-2.75). Conclusion Disease extent and histological response are risk factors for progression to DM or death. Tumor site and surgical margins are risk factors for LR. If disease progression occurs, previous risk factors lose their relevance. In case of isolated LR, time to recurrence is important for decision-making. Radiotherapy seems protective for LR especially in pelvic/axial. Low percentages of LR in extremity tumors and associated toxicity question the need for radiotherapy in extremity Ewing sarcoma.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma
    Hayashi, Masanori
    Baker, Alissa
    Goldstein, Seth D.
    Albert, Catherine M.
    Jackson, Kyle W.
    McCarty, Gregory
    Kahlert, Ulf D.
    Loeb, David M.
    ONCOTARGET, 2017, 8 (45) : 78265 - 78276
  • [22] Local and distant control in non-metastatic pelvic Ewing's sarcoma patients
    Donati, Davide
    Yin, Junqiang
    Di Bella, Claudia
    Colangeli, Marco
    Bacci, Gaetano
    Ferrari, Stefano
    Bertoni, Franco
    Barbieri, Enza
    Mercuri, Mario
    JOURNAL OF SURGICAL ONCOLOGY, 2007, 96 (01) : 19 - 25
  • [23] Risk analysis factors for local recurrence in Ewing's sarcoma WHEN SHOULD ADJUVANT RADIOTHERAPY BE ADMINISTERED?
    Albergo, J. I.
    Gaston, C. L. L.
    Parry, M. C.
    Laitinen, M. K.
    Jeys, L. M.
    Tillman, R. M.
    Abudu, A. T.
    Grimer, R. J.
    BONE & JOINT JOURNAL, 2018, 100B (02): : 247 - 255
  • [24] Ewing's sarcoma: General insights from a rare model
    Davis, Sean
    Meltzer, Paul S.
    CANCER CELL, 2006, 9 (05) : 331 - 332
  • [25] CtDNA release mechanisms in a therapeutic Ewing Sarcoma mouse model
    Eiblwieser, J.
    Krumbholz, M.
    Semper, S.
    Frey, B.
    Nagel, L.
    Bauerle, T.
    Metzler, M.
    KLINISCHE PADIATRIE, 2022, 234 (03): : 178 - 178
  • [26] A Visualized Dynamic Prediction Model for Lymphatic Metastasis in Ewing's Sarcoma for Smart Medical Services
    Li, Wenle
    Xu, Chan
    Hu, Zhaohui
    Dong, Shengtao
    Wang, Haosheng
    Liu, Qiang
    Tang, Zhi-Ri
    Li, Wanying
    Wang, Bing
    Lei, Zhi
    Yin, Chengliang
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [27] Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study
    Jiaqi Shi
    Jianing Yang
    Xin Ma
    Xu Wang
    Journal of Orthopaedic Surgery and Research, 15
  • [28] Development of a Machine Learning-Based Predictive Model for Lung Metastasis in Patients With Ewing Sarcoma
    Li, Wenle
    Hong, Tao
    Liu, Wencai
    Dong, Shengtao
    Wang, Haosheng
    Tang, Zhi-Ri
    Li, Wanying
    Wang, Bing
    Hu, Zhaohui
    Liu, Qiang
    Qin, Yong
    Yin, Chengliang
    FRONTIERS IN MEDICINE, 2022, 9
  • [29] Risk factors for metastasis and poor prognosis of Ewing sarcoma: a population based study
    Shi, Jiaqi
    Yang, Jianing
    Ma, Xin
    Wang, Xu
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2020, 15 (01)
  • [30] RESPONSE TO INITIAL TREATMENT, LOCAL THERAPY MODALITY AND METASTASIS ARE IMPORTANT IN EWING'S SARCOMA
    Kebudi, Rejin
    Ayan, Inci
    Agaoglu, Fulya Yaman
    Darendeliler, Emin
    Ozger, Harzem
    Gorgun, Omer
    Dizdar, Yavuz
    Almac, Zeynep
    Eralp, Levent
    Bilgic, Bilge
    PEDIATRIC BLOOD & CANCER, 2009, 53 (05) : 798 - 799